NEXT GENERATION CANCER DIAGNOSTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-73388 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Next Generation Cancer Diagnostics Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET

7.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Abbott

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Hologic

16.3 F Hoffmann-La Roche Ltd

16.4 Illumina

16.5 Koninklijke Philips NV

16.6 Myriad Genetics

16.7 Almac Group

16.8 Sysmex Corporation

16.9 GE Healthcare

16.10 Qiagen

16.11 Thermo Fisher Scientific

16.12 Novartis AG

16.13 Agilent Technologies

16.14 PerkinElmer

16.15 Genomic Health

16.16 Cepheid

16.17 Opko Health

16.18 Janssen Global Services

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
Next Generation Sequencing
QPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays

By Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others

Companies

Abbott
Hologic
F Hoffmann-La Roche Ltd
Illumina
Koninklijke Philips NV
Myriad Genetics
Almac Group
Sysmex Corporation
GE Healthcare
Qiagen
Thermo Fisher Scientific
Novartis AG
Agilent Technologies
PerkinElmer
Genomic Health
Cepheid
Opko Health
Janssen Global Services

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.